DVANYSEServices-Misc Health & Allied Services, NECFiscal year ends December 31
DAVITA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$187.00−0.31 (-0.17%)
Close on Oct 19, 2026
- Market cap
- $12.36B
- P/E (TTM)
- 15.3
- Dividend yield
- –
DAVITA INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S Dialysis And Related Lab Services with Intersegment | $11.79B | $11.39B | $10.94B | $10.60B | – | – | – | – | – | – | 86.4% | +3.5% |
| U S Dialysis | $11.73B | $11.32B | $10.85B | $10.60B | $10.67B | $10.66B | $10.56B | $10.34B | $9.36B | $9.11B | 86.0% | +3.6% |
| Other Operating Segments with Intersegment | $1.92B | $1.51B | $1.30B | $1.10B | – | – | – | – | – | – | 14.1% | +27.3% |
| Other - Ancillary Services | $1.91B | $1.50B | $1.29B | $1.10B | $1.04B | $1.04B | $957.90M | $1.20B | $1.60B | $1.60B | 14.0% | +27.7% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| U S Dialysis | $2.08B | $2.12B | $1.77B | $1.57B | $1.97B | $1.92B | $1.92B | $1.71B | $2.30B | $1.78B | -1.7% |
| Other - Ancillary Services | $92.38M | $82.66M | -$8.75M | -$96.58M | -$66.00M | -$76.26M | -$189.17M | -$93.79M | -$439.48M | $266.32M | +11.8% |
| DMG - discontinued operations | – | – | – | – | – | – | – | – | – | -$104.23M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Davita's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.